Glenmark
A new way for a new world

May 16, 2012

The Manager
Listing Dept,
The National Stock Exchange of India Ltd
Plot No. C/1,G Block
Bandra Kurla Complex
Bandra (E) Mumbai-400051

Dear Sir,

We are enclosing herewith a press release informing **"Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets from U.S. FDA"**, for your information and record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Ltd.

Marshall Mendonza
Vice President & Company Secretary

Tel: 4018 9999 / 4018 9879
Fax No: 4018 9986 (Legal & Secretarial Dept.)

Encl: as above

Glenmark Generics Ltd.

glenmark
A new way for a new world

Press Release For Immediate Release

Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets from the U.S. FDA

May 16, 2012: Glenmark Generics Inc, USA, the United States subsidiary of Glenmark Generic Limited, announced today that the United States Food and Drug Administration (U.S. FDA) has granted tentative approval for zolmitriptan orally disintegrating tablets, its generic version of AstraZeneca's Zomig-ZMT® Tablets.

The tentative approval is for the 2.5 mg and 5 mg orally disintegrating tablets of zolmitriptan and constitutes one of the first tentative approvals granted by the FDA for a generic version of the drug.

Glenmark was granted tentative approval for its immediate release version of zolmitriptan tablets in September 2011. The Company will be vertically integrated by manufacturing the active pharmaceutical ingredient for both of its zolmitriptan products and plans to launch in May 2013 upon final approval from the U.S. FDA.

According to IMS Health for the 12 month period ending March 2012, zolmitriptan immediate release tablets and orally disintegrating tablets achieved sales of USD 131 million and USD 31 million, respectively.

Glenmark's current portfolio consists of 80 products authorized for distribution in the U.S. marketplace and 38 ANDA's pending approval with the U.S. FDA. The Company remains focused on strategic planning and development and continues its aggressive filing schedule for new ANDA submissions.

About Glenmark Generics Limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in over 80 countries, including the US, various countries in the EU, South America and India.

#####

For further information, please contact:
Jason D'Souza / Rajdeep Barooah
Glenmark, Mumbai, India
Tel: [+91 22] 40189919/984 Email : connect@glenmark-generics.com